Press Releases CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H2013

Delayed Nasdaq Other stock markets 09:57:41 2024-04-29 am EDT			5-day change	1st Jan Change
0.2107 ^USD	-2.00%		+5.83%	-83.41%

Apr. 23	Transcript : CNS Pharmaceuticals, Inc. - Special Call
Apr. 01	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CNS Pharmaceuticals to Present at the LSX World Congress 2024	Apr. 24	AQ
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break, the CNSP Opportunity	Apr. 23	AQ
CNS Pharmaceuticals to Present at Two Investor Conferences in April	Apr. 02	AQ
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering	Jan. 30	AQ
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors	Jan. 19	AQ
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	Jan. 18	AQ
CNS Pharmaceuticals : Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin - Form 8-K	Dec. 18	PU
How CNS Pharmaceuticals Is Taking a Different Approach to Find a Treatment for Glioblastoma, a Cancer with a Poor Prognosis and No Cure	Dec. 07	AQ
CNS Pharmaceuticals to Release Interim Data by the End of the Year for Potential Glioblastoma Drug Candidate	Nov. 17	AQ
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study before Year End	Nov. 16	AQ
CNS Pharmaceuticals : Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End - Form 8-K	Nov. 15	PU
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference	23-10-20	AQ
CNS Pharmaceuticals : Regulation FD Disclosure - Form 8-K	23-10-18	PU
Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals Innovative Approach to Treatment Could Offer Hope	23-10-17	AQ
CNS Pharmaceuticals Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date	23-10-12	AQ
CNS Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	AQ
CNS Pharmaceuticals Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM after Failure of Standard First Line Therapy	23-08-15	AQ
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones	23-08-15	AQ
CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference	23-07-28	AQ
CNS Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest	23-06-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H2013

Press Releases

Filters